Transaction · 0001674236-26-000022

CAREY STEPHEN P.

CAREY STEPHEN P., SVP, CFO, reported an open-market or private sale at ANI PHARMACEUTICALS INC involving 2850.000000 shares for an estimated $207480.00. Reported holdings after the transaction were 171843.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSVP, CFO
ANIPANI PHARMACEUTICALS INC
Filing timeSep 01
Trade dateAug 31, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$71.92
Pre-filing
1mo ago +10.2%1w ago +3.1%1d ago +1.3%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

ANIP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ANIP since 2026-09-01Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001674236-26-000022
Common Stock
Transaction date
Aug 31, 2026
Filed Sep 01, 2026, 10:18 PM · 1d delay
Shares
2.85k sh
$7.28k per share
Estimated value
-$20.7M
Computed from shares × price
Holdings after
171k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SVP & CFO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

  2. F2

    The shares were sold in multiple trades at prices ranging from $71.89 to $73.36. The price reported above reflects the weighted average sales price.

Original filing · 0001674236-26-000022
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ANIP